Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse

TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 potential as an individualized cancer immunotherapy ...
Business Insider

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors

BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors ...
Morningstar

Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025

Authors: C. Lebbe, R. Bahleda, E. Ezine, B. Baroudjian, M. Sakkal, E. Rowinski, A. Vinceneux, S. Champiat, K. Bidet Huang, N. Stojkowitz, H. Makhloufi, A. Sadoun, A ...
finanzen.at

Transgene's TG4050 Shows 100% Two-Year Disease-Free Survival In Phase I Head & Neck Cancer Trial

Transgene (TRGNF, TNG.PA), a biotechnology company developing virus-based immunotherapies for cancer, announced the preprint ...
Business Insider

New Phase I Immunological Data Presented at SITC 2025 Support TG4050’s Potential Role in Preventing Cancer Relapse

New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC [*] patients Comprehensive immunogenicity data demonstrate TG4050’s ...